Comparison of Topical 0.15% Gancyclovir Gel Versus 0.3% Hypromellose Gel for the Treatment of Herpes Zoster Keratitis

Stopped early · Phase 2

Conditions studied: Herpes Zoster Keratitis

In brief

The purpose of this study is to evaluate the efficiency of topical gancyclovir 0.15% in the treatment of herpes zoster keratitis. Half the patients will receive the study drug while the other half of the patients will receive the placebo

Key facts

Study ID

NCT02382588

Run by

Northwestern University

People needed

8

Starts

2013-12-10

Expected to finish

2020-05-11

Last updated by the study team

2021-07-08

Who can join

Age: 18 and older, up to 95. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• age 18 and above
• have not been on gancyclovir gel or any other form of topical antiviral therapy for the past month
• able and willing to attend subsequent follow-up visits

You may not qualify if…

• Associated retinitis
• patients who are allergic to gancyclovir
• patients who will require systemic or intra-vitreal gancyclovir therapy
• patients who are pregnant or breastfeeding

Where it is running

• Northwestern University — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.